Lung cancer (Amsterdam, Netherlands)
August 20, 2026 · via Europe PMC
Therapeutic evolution: Adoption of newly approved systemic therapies in resected stage IB-IIIA NSCLC in the United States.
Gray JE, Thoele K, Richey M, Boualam N, Schwed K, Brechtelsbauer E, Ma Q, Sheffield KM.
AI summary — for doctors, generated from the abstract only
US real-world data show rapid uptake of new perioperative therapies in resected stage IB-IIIA NSCLC: by 2023, 48.6% of stage II-IIIA patients received immunotherapy and 58% of EGFR-mutant patients received osimertinib.
What was studied
A retrospective observational cohort of 14,638 patients with resected stage IB-IIIA NSCLC (2019-2023) from US oncology practice records.
Key findings
- 58.3% received any systemic therapy (47.7% platinum, 18.1% immunotherapy, 4.9% targeted), mostly adjuvant
- Immunotherapy and osimertinib use increased over time
- Median DFS 46.2 months overall, 38.4 months in stage II-IIIA
- 3-year OS 72.9%
Clinical relevance
This documents practice evolution and suggests remaining gaps, as many eligible patients still receive no systemic therapy.
Who should care
Limitations
Real-world EHR data with potential missing biomarker or treatment information.
New perioperative lung cancer therapies are being adopted quickly, but many patients still receive none.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
Objectives
Evidence is limited regarding use of immunotherapies and targeted therapies in early-stage and locally advanced non-small cell lung cancer (NSCLC) in clinical practice. This retrospective, observational cohort study used health records from US oncology practices to describe treatment patterns and evaluate outcomes in patients with resected stage IB-IIIA NSCLC.
Materials and methods
Adult patients with stage IB-IIIA NSCLC who completed primary surgery from January 2019-December 2023 (n = 14,638) were included, with potential follow-up through August 2024. Subset analyses of stage II-IIIA NSCLC (n = 9,932) were also conducted. Neoadjuvant and adjuvant therapy use was described by stage, biomarker status, and year of surgery. Outcomes included disease-free survival (DFS) and overall survival (OS).
Results
Among 14,638 patients (median age, 70 years) 32.1 % were diagnosed with stage IB, 39.2 % with stage II, and 28.6 % with stage III disease. During the study period, 58.3 % received any systemic treatment (47.7 % platinum-based chemotherapy, 18.1 % immunotherapy, and 4.9% targeted therapy), primarily in the adjuvant setting. Immunotherapy and osimertinib use increased over time: by 2023, 48.6 % of patients with stage II-IIIA disease received immunotherapy, and 58.0 % of patients with stage IB-IIIA EGFR-mutant NSCLC received osimertinib. Median DFS was 46.2 months for overall study cohort and 38.4 months for patients with stage II-IIIA disease. The 3-year OS was 72.9 % for the overall study cohort.
Conclusions
The treatment landscape for early-stage and locally advanced NSCLC has rapidly evolved with recent approvals. Real-world data from large clinical practice studies provide value in understanding use and outcomes of new treatments and identifying potential clinical practice gaps and unmet need.
DOI
10.1016/j.lungcan.2026.109586
PMID
42636546
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed